Mammography AI Moves Closer to Standard of Care, But FDA Has Yet to Catch Up
A new review of the MASAI trial argues that AI-augmented mammography may already be functionally standard in some screening settings, even if U.S. regulators have not fully formalized that view. The disconnect highlights a growing problem in healthcare: evidence can move faster than policy.
The MASAI trial has become a provocative marker in the debate over clinical AI because it suggests that AI-augmented mammography may be ready for routine use. If that interpretation holds, the FDA’s slower pace could become more than an administrative issue—it could shape access to care.
What makes this especially significant is that breast imaging is one of the clearest use cases for AI in medicine. The workflow is measurable, the output is interpretable, and the clinical value proposition is straightforward: improve detection, reduce missed cancers, and potentially make screening more efficient. In other words, this is the kind of application where AI should succeed if it can succeed anywhere.
But translating trial results into standard practice is never automatic. Regulators want not only evidence that a system works, but evidence that it works reliably across settings, populations, and deployment models. That caution is understandable, yet it can also create a lag between the evidence base and real-world adoption.
The larger story is that imaging AI is leaving the demo phase and entering the policy phase. The key question is no longer whether AI can improve performance in narrow settings; it is whether the regulatory system can keep up with the pace at which those gains become clinically meaningful.